Skip to main content
All lobbying filings

GSK (FKA GLAXOSMITHKLINE INC.)

Lobbying for GSK (FKA GLAXOSMITHKLINE INC.)

 Filing 3rd Quarter - Report
3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $1,700,000.00 expenses · posted Oct 20, 2025

Official filing document

 Bills named in this filing 46
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HR 3944
    Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026
  • HR 4121
    Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
  • HRES 566
    Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to titl…
  • HCONRES 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
  • HR 4213
    Department of Homeland Security Appropriations Act, 2026
  • S 2256
    Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
  • HR 5304
    Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
  • S 2587
    Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
  • HR 5342
    Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
  • S 2354
    Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
  • S 43
    Skinny Labels, Big Savings Act
  • S 708
    RESTORE Patent Rights Act of 2025
  • S 1040
    Drug Competition Enhancement Act
  • S 1041
    Affordable Prescriptions for Patients Act
  • S 1095
    Stop STALLING Act
  • S 1096
    Preserve Access to Affordable Generics and Biosimilars Act
  • S 1097
    Interagency Patent Coordination and Improvement Act of 2025
  • S 1546
    Patent Eligibility Restoration Act of 2025
  • S 1553
    PREVAIL Act
  • S 2276
    ETHIC Act
  • S 2620
    REMEDY Act
  • S 2658
    Medication Affordability and Patent Integrity Act
  • HR 890
    Stopping Pharma’s Ripoffs and Drug Savings For All Act
  • HR 1574
    RESTORE Patent Rights Act of 2025
  • HR 3152
    Patent Eligibility Restoration Act of 2025
  • HR 3160
    PREVAIL Act
  • HR 3269
    ETHIC Act
  • HR 4570
    Interagency Patent Coordination and Improvement Act of 2025
  • S 2296
    National Defense Authorization Act for Fiscal Year 2026
  • S 652
    Protecting Patients from Deceptive Drug Ads Act
  • S 832
    EPIC Act of 2025
  • S 864
    HELP Copays Act
  • S 882
    Patients Before Middlemen Act
  • S 891
    Bipartisan Health Care Act
  • S 1302
    Increasing Transparency in Generic Drug Applications Act
  • S 1414
    Expedited Access to Biosimilars Act
  • S 1784
    MAPS Act
  • S 1954
    Biosimilar Red Tape Elimination Act
  • HR 946
    ORPHAN Cures Act
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • HR 2214
    DRUG Act
  • HR 4132
    Prescription Information Modernization Act of 2025
  • HR 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • S 339
    Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
  • HR 6283
    DRUG Act
 Lobbying activity 5
Budget/Appropriations

H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 3944: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Department of Homeland Security Appropriations Act, 2026 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 Government funding policy issues

Copyright/Patent/Trademark

S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 1574: RESTORE Patent Rights Act of 2025 H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent use codes policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues

Trade (domestic/foreign)

S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues

Health Issues

S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864, HELP Copays Act - A bill to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes. S. 882, Patients Before Middlemen Act, and other legislation related to pharmacy benefit manager (PBM) reform. Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Provisions related to the pharmaceutical industry. S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 1302: Increasing Transparency in Generic Drug Applications Act S. 1414: Expedited Acccess to Biosimilars Act S. 1784: MAPS Act S. 1954: Biosimilar Red Tape Elimination Act H.R. 1: One Big Beautiful Bill Act H.R. 946: Orphan Cures Act H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R. 2214: DRUG Act H.R. 4132: Prescription Information Modernization Act of 2025 HR 6283: Delinking Revenue from Unfair Gouging (DRUG) Act - bill aimed at reforming practices of Pharmacy Benefit Managers (PBMs) by delinking their revenue from the list price of prescription drugs Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues Accelerated approval policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order, Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order, Lowering Drug Prices by Once Again Putting Americans First

Medicare/Medicaid

H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act S. 339, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act - To amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests. Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem